Rene Gatsinga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rene Gatsinga has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Yu Guang Tan
Singapore Gen Hosp, Dept Urol, 16 Coll Rd,Block 4 Level 1, Singapore 169854, Singapore
2 shared publications- Benjamin J. H. Lim
Department of Urology, Singapore General Hospital, Singapore 169608, Singapore
1 shared publication - Jacinda Tan
Neuroscience and Behavioural Disorders Programme, Duke-NUS Medical School, Singapore
1 shared publication Jeffrey Kit Loong Tuan
Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore
1 shared publication- Jeffrey Kit Loong Tuan
National Cancer Centre Singapore 1 , Singapore, Singapore
1 shared publication Johan Chan
Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
1 shared publication
Latest Publications
- Open Access
Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer Survivors: The Hidden Toll
Background and Objectives: Radiation therapy (RT) plays a crucial role in managing prostate cancer, offering effective disease control and improving survival rates in both localized and recurrent cases. However, RT can lead to hemorrhagic cystitis, a significant late complication resulting in chronic morbidity and other health issues. This study aims to evaluate the real-world incidence of radiation-induced hemorrhagic cystitis requiring surgical intervention. Materials and Methods: This retrospective cohort study analyzed data from prostate cancer survivors treated for hematuria at our center between January 2014 and January 2024. Patients were included if cystoscopy identified radiation cystitis as the cause of hematuria. Descriptive statistics were used, and binomial logistic regression analyses with univariate and multivariate analysis were performed to identify risk factors for worse outcomes. Results: Fifty-two patients met the inclusion criteria. The estimated cumulative incidence at a median follow-up of 5.3 years was 4.5%. Among the participants, 21.2% required more than two transurethral bladder fulguration (TUBF) procedures, and 38.5% needed more than two hospital admissions for hematuria management. The median time to the first fulguration was 64 months. Blood transfusions were necessary in 53.8% of cases, and 38.5% required hyperbaric oxygen therapy. Ultimately, 5.8% of the patients underwent cystectomy. Univariate analysis identified ischemic heart disease (IHD) and antiplatelet therapy as significant risk factors (OR: 5.17 and 5.18, respectively), along with longer time to first fulguration (OR: 5.02). Multivariate analysis confirmed antiplatelet therapy (OR: 2.8, p = 0.05) and time to first TUBF (OR: 1.8, p = 0.02) as significant predictors of multiple procedures. Conclusions: Radiation cystitis remains a significant burden on prostate cancer survivors. Patients on antithrombotic agents, those with delayed initial presentations, and those who received radiation as salvage therapy are more likely to experience higher morbidity.
Open AccessRadiation-Induced Hemorrhagic Cystitis in Prostate Cancer Survivors: The Hidden Toll
Background and Objectives: Radiation therapy (RT) plays a crucial role in managing prostate cancer, offering effective disease control and improving survival rates in both localized and recurrent cases. However, RT can lead to hemorrhagic cystitis, a significant late complication resulting in chronic morbidity and other health issues. This study aims to evaluate the real-world incidence of radiation-induced hemorrhagic cystitis requiring surgical intervention. Materials and Methods: This retrospective cohort study analyzed data from prostate cancer survivors treated for hematuria at our center between January 2014 and January 2024. Patients were included if cystoscopy identified radiation cystitis as the cause of hematuria. Descriptive statistics were used, and binomial logistic regression analyses with univariate and multivariate analysis were performed to identify risk factors for worse outcomes. Results: Fifty-two patients met the inclusion criteria. The estimated cumulative incidence at a median follow-up of 5.3 years was 4.5%. Among the participants, 21.2% required more than two transurethral bladder fulguration (TUBF) procedures, and 38.5% needed more than two hospital admissions for hematuria management. The median time to the first fulguration was 64 months. Blood transfusions were necessary in 53.8% of cases, and 38.5% required hyperbaric oxygen therapy. Ultimately, 5.8% of the patients underwent cystectomy. Univariate analysis identified ischemic heart disease (IHD) and antiplatelet therapy as significant risk factors (OR: 5.17 and 5.18, respectively), along with longer time to first fulguration (OR: 5.02). Multivariate analysis confirmed antiplatelet therapy (OR: 2.8, p = 0.05) and time to first TUBF (OR: 1.8, p = 0.02) as significant predictors of multiple procedures. Conclusions: Radiation cystitis remains a significant burden on prostate cancer survivors. Patients on antithrombotic agents, those with delayed initial presentations, and those who received radiation as salvage therapy are more likely to experience higher morbidity.
- Open Access
- 1 September 2024
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (9) , 1786-1794
Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings
Background: Various treatment regimens are now available for metastatic castrate-resistant prostate cancer (CRPC). This work evaluates the real-world prescription patterns of CRPC in a large tertiary care center and the factors influencing them. Methods: Health records of 330 patients with de novo metastatic hormone-sensitive prostate cancer (HSPC), treated and progressed to CRPC between 2016 and 2020, were reviewed from a prospective uro-oncological database. We studied their demographics, medical co-morbidities, treatment utilization patterns before and after progression to CRPC, and survival outcomes. Results: The median age was 74 years [interquartile range (IQR), 67–80 years] at diagnosis of CRPC. At CRPC, beyond androgen deprivation therapy (ADT) monotherapy, 70.3% (n=232) of patients received at least one additional line, 21.5% (n=71) received two lines, and 5.5% (n=18) received three lines of systemic treatments. As first-line treatment, novel hormonal agents (NHAs) were the most prescribed at 57.6% (n=190). The likelihood of receiving treatment was associated with age vs. 17 months, OR 1.72, PConclusions: More than one in four patients do not receive any additional treatment line beyond ADT monotherapy and have worse survival outcomes. Health status, prescribing physician, and treatment at HSPC appear to affect prescription patterns at the CRPC stage.
- 1 September 2024
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (9) , 1786-1794
Open AccessLost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings
Background: Various treatment regimens are now available for metastatic castrate-resistant prostate cancer (CRPC). This work evaluates the real-world prescription patterns of CRPC in a large tertiary care center and the factors influencing them. Methods: Health records of 330 patients with de novo metastatic hormone-sensitive prostate cancer (HSPC), treated and progressed to CRPC between 2016 and 2020, were reviewed from a prospective uro-oncological database. We studied their demographics, medical co-morbidities, treatment utilization patterns before and after progression to CRPC, and survival outcomes. Results: The median age was 74 years [interquartile range (IQR), 67–80 years] at diagnosis of CRPC. At CRPC, beyond androgen deprivation therapy (ADT) monotherapy, 70.3% (n=232) of patients received at least one additional line, 21.5% (n=71) received two lines, and 5.5% (n=18) received three lines of systemic treatments. As first-line treatment, novel hormonal agents (NHAs) were the most prescribed at 57.6% (n=190). The likelihood of receiving treatment was associated with age vs. 17 months, OR 1.72, PConclusions: More than one in four patients do not receive any additional treatment line beyond ADT monotherapy and have worse survival outcomes. Health status, prescribing physician, and treatment at HSPC appear to affect prescription patterns at the CRPC stage.
- 21 March 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (3) , e248127
Priapism mimic: penile metastasis from hepatocellular carcinoma
We describe the case of a metastatic penile tumour of hepatocellular origin treated with surgical resection.
- 21 March 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (3) , e248127
Priapism mimic: penile metastasis from hepatocellular carcinoma
We describe the case of a metastatic penile tumour of hepatocellular origin treated with surgical resection.